

# Burkina Faso

## Tuberculosis profile

Population 2015

18 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.6 (0.97–2.4)	9 (5.4–14)
Mortality (HIV+TB only)	0.27 (0.12–0.48)	1.5 (0.67–2.7)
Incidence (includes HIV+TB)	9.4 (6.1–13)	52 (34–74)
Incidence (HIV+TB only)	0.89 (0.57–1.3)	4.9 (3.2–7.1)
Incidence (MDR/RR-TB)**	0.4 (0.018–0.77)	2.2 (0.1–4.3)

Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	0.61 (0.33–0.89)	2.2 (0.24–4.2)	2.8 (0.58–5.1)
Males	0.44 (0.26–0.61)	6.1 (4.2–8)	6.6 (4.5–8.7)
Total	1 (0.67–1.4)	8.3 (6.3–10)	9.4 (6.1–13)

TB case notifications, 2015

Total cases notified	5 808
Total new and relapse	5 594
- % tested with rapid diagnostics at time of diagnosis	2%
- % with known HIV status	97%
- % pulmonary	85%
- % bacteriologically confirmed among pulmonary	84%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	60% (42–92)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.21 (0.11–0.36)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	504	9%
- on antiretroviral therapy	427	85%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			220 (28–420)
Estimated % of TB cases with MDR/RR-TB	2.8% (0.1–6.7)	21% (2.2–39)	
% notified tested for rifampicin resistance	2%	38%	283
MDR/RR-TB cases tested for resistance to second-line drugs			20
Laboratory-confirmed cases		MDR/RR-TB: 54, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 36, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	81%	5 322
Previously treated cases, excluding relapse, registered in 2014	75%	456
HIV-positive TB cases, all types, registered in 2014	74%	564
MDR/RR-TB cases started on second-line treatment in 2013	62%	42
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2016

National TB budget (US\$ millions)	9.7
Funding source: 3% domestic, 16% international, 81% unfunded	


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence  
Notified (new and relapse)  
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



New and relapse  
Retreatment, excluding relapse  
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)



Unfunded  
Funded internationally  
Funded domestically